Zobrazeno 1 - 3
of 3
pro vyhledávání: ''
Publikováno v:
Retrovirology, Vol 16, Iss 1, Pp 1-14 (2019)
Retrovirology
Retrovirology
Human T-cell leukemia virus type-1 (HTLV-1) causes adult T-cell leukemia/lymphoma (ATL), HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP), and other inflammatory diseases. There is no disease-specific difference in viral strains, a
Autor:
Peter A. Barry, Andrew A. Lackner, Pyone P. Aye, Janice E. Clements, Haitao Hu, Lucio Gama, Drew Weissman
Publikováno v:
Retrovirology, Vol 8, Iss 1, p 57 (2011)
Retrovirology
Hu, Haitao; Gama, Lucio; Aye, Pyone P; Clements, Janice E; Barry, Peter A; Lackner, Andrew A; et al.(2011). SIV antigen immunization induces transient antigen-specific T cell responses and selectively activates viral replication in draining lymph nodes in retroviral suppressed rhesus macaques. Retrovirology, 8(1), 57. doi: http://dx.doi.org/10.1186/1742-4690-8-57. Retrieved from: http://www.escholarship.org/uc/item/3j49q153
Retrovirology
Hu, Haitao; Gama, Lucio; Aye, Pyone P; Clements, Janice E; Barry, Peter A; Lackner, Andrew A; et al.(2011). SIV antigen immunization induces transient antigen-specific T cell responses and selectively activates viral replication in draining lymph nodes in retroviral suppressed rhesus macaques. Retrovirology, 8(1), 57. doi: http://dx.doi.org/10.1186/1742-4690-8-57. Retrieved from: http://www.escholarship.org/uc/item/3j49q153
Background HIV infection causes a qualitative and quantitative loss of CD4+ T cell immunity. The institution of anti-retroviral therapy (ART) restores CD4+ T cell responses to many pathogens, but HIV-specific responses remain deficient. Similarly, th
Autor:
Kouzi Yamaguti, Ryuta Sakuma, Yasuhiro Ikeda, Fumiya Hirayama, Takayuki Miyazawa, Eiji Sato, Kazuta Yasui, Takeki Sugiyama, Naoko Misawa, Yasuhito Nakatomi, Hirohiko Kuratsune, Rika A. Furuta
Publikováno v:
Retrovirology, Vol 8, Iss 1, p 20 (2011)
Retrovirology
Retrovirology
Background The involvement of xenotropic murine leukemia virus-related virus (XMRV) in prostate cancer (PC) and chronic fatigue syndrome (CFS) is disputed as its reported prevalence ranges from 0% to 25% in PC cases and from 0% to more than 80% in CF